Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics
RYTM Price/Volume Stats
| Current price | $56.12 | 52-week high | $68.58 |
| Prev. close | $55.48 | 52-week low | $35.17 |
| Day low | $55.47 | Volume | 1,520,000 |
| Day high | $58.16 | Avg. volume | 548,620 |
| 50-day MA | $56.14 | Dividend yield | N/A |
| 200-day MA | $46.94 | Market Cap | 3.45B |
RYTM Stock Price Chart Interactive Chart >
Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.
RYTM Price Returns
| 1-mo | -4.93% |
| 3-mo | 6.29% |
| 6-mo | 31.95% |
| 1-year | 21.08% |
| 3-year | 385.89% |
| 5-year | 133.93% |
| YTD | 22.08% |
| 2023 | 57.86% |
| 2022 | 191.78% |
| 2021 | -66.43% |
| 2020 | 29.49% |
| 2019 | -14.58% |
Loading social stream, please wait...